Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immatics
Biotech
Immatics leaps into phase 3 on strength of early-stage PFS data
Immatics is starting a pivotal trial of its melanoma cell therapy in light of the response and PFS results seen in a phase 1b study.
Nick Paul Taylor
Oct 10, 2024 8:49am
ESMO: Bristol Myers axes Immatics' bispecific after $150M bet
Sep 16, 2024 6:59am
With $1.7B Immatics deal, Moderna bets again on cancer vaccines
Sep 11, 2023 8:12am
Immatics' stock soars on PRAME prospect's solid tumor data
May 3, 2023 9:35am
GSK severs Immatics partnership in further T-cell retreat
Nov 17, 2022 11:00am
BMS-backed Immatics touts early data, prompting $110M offering
Oct 10, 2022 1:23pm
